MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial PROTOSTAR to Evaluate Guselkumab in Pediatric Psoriasis Patients news with additional features

DGAPNews MorphoSys AG Key words Study25.09.2018 2201 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany September 25 2018 MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial PROTOSTAR to Evaluat...